drugset / Trial / NCT05150691
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Timeline
- Start
- 2022-01-31
- Primary completion
- 2026-04
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | — | Oral |
| Subject | Ritonavir | Other / unclassified | — | Oral |
| Subject | TRASTUZUMAB PAMIRTECAN | Unknown | — | Intravenous |
| Background | Pertuzumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.